NIAID CLINICAL PRODUCTS CENTER (CPC)
ID: NIAID-75N93024R00018Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/37bf18ce38224e7abb00f02032a50a4c/view
Timeline
    Description

    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the NIAID Clinical Products Center (CPC) contract, aimed at supporting clinical trials focused on immunologic, infectious, and allergic diseases. The contract will provide essential pharmacy and pharmaceutical oversight for national and international clinical trials, ensuring product integrity, participant safety, and compliance with regulatory standards, while also expanding support for additional NIH-funded trials and emergency public health programs as needed. This initiative is critical for advancing research in various immune-mediated diseases, including asthma, autoimmune disorders, and organ transplant rejection. Interested parties should prepare to submit proposals electronically via the NIAID electronic Contract Proposal Submission (eCPS) website, with the presolicitation notice expected to be published on or around October 18, 2024. For further inquiries, contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov.

    Point(s) of Contact
    Deborah Blyveis
    (240) 669-5143
    blyveisd@niaid.nih.gov
    Emily Bannister
    emily.bannister@nih.gov
    Files
    Title
    Posted
    Presol Notice_Final CPC.pdf
    The NIAID Clinical Products Center (CPC) presolicitation notice outlines the intent to support clinical trials focused on immunologic, infectious, and allergic diseases. This initiative, led by the NIAID within the NIH, aims to ensure product integrity, participant safety, and compliance with pharmacy regulations. The notice describes the services required, such as study product management, inventory, and testing, needed for a diverse array of immune-mediated diseases, including asthma, autoimmune disorders, and organ transplant rejection. A prior seven-year contract with EMINENT Services Corporation established support for the pharmacy oversight functions. The new contract will maintain these responsibilities and expand support for additional NIH-funded trials, including emergency public health programs when necessary. Proposals will be evaluated based on technical plans, facilities, personnel expertise, and project management, with a total value weight of 100 points. The documentation emphasizes compliance with federal regulations and the necessity for contractors to meet strict licensing and operational criteria. The presolicitation is set to be published electronically, inviting any qualified offeror to submit proposals, reflecting the government’s commitment to enhancing healthcare research through structured contract guidelines.
    Sources Sought.pdf
    Lifecycle
    Title
    Type
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Presolicitation
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Currently viewing
    Sources Sought
    Similar Opportunities
    A--Request for Proposals - Phase I Clinical Trials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Phase I Clinical Trials focused on the development of small molecule and biologics therapeutics. The objective is to engage qualified contractors to conduct comprehensive clinical trials, including protocol development, trial management, and reporting to regulatory agencies, with a specific emphasis on safety, tolerability, and pharmacokinetics of investigational drugs. This initiative is crucial for advancing therapeutic development in neurological disorders and ensuring compliance with federal regulations regarding human subjects. Proposals are due by October 11, 2024, with a contract performance period extending from April 1, 2025, to March 31, 2035, and a maximum contract value of $233,227,446. For further inquiries, interested parties may contact Evan C. Feely at evan.feely@nih.gov or +1 301 827 5301.
    A--BPCA Pediatric Trials Network
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for an Indefinite Quantity Contract to establish and maintain an infrastructure for conducting pediatric clinical trials under the Best Pharmaceuticals for Children Act (BPCA). The primary objective of this procurement is to advance pediatric drug development by ensuring compliance with federal regulations and ethical standards in clinical research, including the protection of human subjects and quality control measures. This initiative is crucial for enhancing the understanding and safety of medications for children, thereby improving healthcare outcomes in pediatric populations. Proposals are due by November 4, 2024, with a performance period extending from May 19, 2025, to May 18, 2033, and a funding range between $2,500 and $149 million, contingent on successful contract performance. Interested parties can contact Elizabeth J. Osinski at eo43m@nih.gov or by phone at 240-550-5028 for further information.
    NIAID PROFESSIONAL, SCIENTIFIC AND TECHNICAL SUPPORT SERVICES (PSTSS)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is issuing a presolicitation notice for professional, scientific, and technical support services under RFP number 75N93023R00010. This procurement aims to secure a re-competition of existing contracts to support NIAID's mission in research, vaccine development, and management of infectious diseases, with key tasks including laboratory support, clinical trials, and consultancy in various scientific specialties. The anticipated contract duration is five years, commencing on June 1, 2025, with proposals expected to be submitted electronically after the RFP release around October 24, 2024. Interested vendors should contact Rosemary Gomes at Rosemary.Gomes@nih.gov or Kristel Turansky at Kristel.Turansky@nih.gov for further information.
    PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under Request for Proposal (RFP) No. 75N95024R00003. The primary objective of this procurement is to acquire, analyze, create, regulate, and distribute a variety of drug compounds essential for advancing research on drug abuse and addiction, including controlled and uncontrolled substances such as morphine, methadone, and various cannabinoid preparations. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement for a five-year period, is crucial for supporting the drug abuse research community by ensuring the availability of authentic drug products while adhering to federal regulations. Proposals must be submitted electronically by November 15, 2024, and interested parties can contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov for further information.
    A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small businesses for the Small Business Innovation Research (SBIR) program, aimed at fostering innovative research that aligns with their mission needs. This solicitation, identified as PHS-2025-1, invites proposals across a wide range of health-related topics, including cancer research, aging, infectious diseases, and mental health, with the goal of stimulating technological innovation and enhancing commercialization in the healthcare sector. Eligible small businesses are encouraged to demonstrate the technical feasibility and commercial potential of their projects, with a closing date for proposal submissions set for October 18, 2024. For further inquiries, interested parties can contact Callie Prassinos at Callie.Prassinos@NIH.gov or Julie Rodriguez at ncioasbir@mail.nih.gov.
    IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the Immune Epitope Database and Analysis Program, aimed at enhancing research capabilities related to infectious diseases, allergies, and autoimmunity. The program seeks to provide a comprehensive resource for researchers to explore data on antibody and T-cell epitopes, with a focus on maintaining high standards of compliance and transparency in research practices. Proposals are due by November 19, 2024, with a base performance period from October 15, 2025, to October 14, 2026, and potential extensions for up to four additional years. Interested parties can contact Brandon de White at whitebra@niaid.nih.gov or Tom Bahrami at bahramit@niaid.nih.gov for further information.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Center for Advancing Translational Sciences (NCATS), is seeking qualified small businesses to provide Chemistry, Manufacturing, and Controls (CMC) and related services for the development of drug products. The objective of this procurement is to support the Therapeutic Development Branch in ensuring the delivery of drug products of sufficient quality and quantity for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic candidates through the drug development pipeline. This opportunity is part of a Small Business Sources Sought notice, aimed at gathering information on the capabilities of small businesses to fulfill these requirements, with a focus on compliance with applicable regulations and the potential for a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract. Interested vendors must submit their capability statements by 10:00 AM Eastern Time on July 21, 2024, to Michelle Cecilia at michelle.cecilia@nih.gov.
    A--NIH NeuroBioBank Brain and Tissue Repository
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the NIH NeuroBioBank Brain and Tissue Repository project. The objective is to acquire post-mortem human brain tissue from a diverse range of donors, including those with various neurological, psychiatric, and neurodevelopmental disorders, to support research efforts in these fields. This initiative is crucial for enhancing the understanding and treatment of such disorders, with the NIH aiming to support multiple awardees capable of acquiring between 70 to 150 unique human donors annually over a five-year contract period. Interested parties should contact Rieka N. Plugge at rieka.plugge@nih.gov or +1 301 827 7515 for further details, with proposals expected to be submitted electronically via the eCPS website following the solicitation release, anticipated within 15 days of this notice.
    Clinical Research Operations and Management System (CROMS) v2.0
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) National Institute on Aging (NIA), is seeking responses for the Clinical Research Operations and Management System (CROMS) v2.0 through a Sources Sought notice. The primary objective is to enhance and maintain the CROMS, which supports the management of over 1,000 clinical trials and 3,000 active grants, by providing comprehensive administrative and scientific information management. This initiative is critical for advancing research on aging and ensuring compliance with federal regulations while leveraging advanced technologies such as cloud services and AI for efficient data handling and reporting. Interested parties must submit their responses electronically to Karen Mahon at karen.mahon@nih.gov by 9:00 a.m. Eastern on October 15, 2024, with an industry day scheduled for October 28, 2024.
    Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the "Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability" through a Special Notice. The objective of this procurement is to establish a long-term partnership focused on developing a flexible and rapid response capability for vaccine development against pandemic influenza and other priority pathogens, initially emphasizing influenza mRNA vaccine development. This initiative is critical for enhancing the nation's preparedness and response to emerging infectious diseases, ensuring readiness to pivot quickly in the face of public health threats. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.